Literature DB >> 17587350

Fc gamma receptor IIa (CD32) polymorphism and antibody responses to asexual blood-stage antigens of Plasmodium falciparum malaria in Sudanese patients.

A Nasr1, N C Iriemenam1, M Troye-Blomberg1, H A Giha1, H A Balogun1, O F Osman1, S M Montgomery1, G ElGhazali1, K Berzins1.   

Abstract

In a prospective clinical study in New Halfa Teaching Hospital, the possible association between FcgammaRIIa-R/H131 polymorphism and anti-malarial antibody responses with clinical outcome of Plasmodium falciparum malaria among Sudanese patients was investigated. A total of 256 individuals were consecutively enrolled, comprising 115 patients with severe malaria, 85 with mild malaria and 56 malaria-free controls. Genotyping of FcgammaRIIa-R/H131 dimorphism was performed using gene-specific polymerase chain reaction (PCR) amplification with allele-specific restriction enzyme digestion of the PCR product. The antibody responses to asexual blood-stage antigens were assessed by an enzyme-linked immunosorbent assay. The frequency of the FcgammaRIIa-R/R131 genotype was significantly higher in those with severe malaria when compared with patients with mild malaria, while the FcgammaRIIa-H/H131 genotype showed a significant association with mild malaria. A reduced risk of severe malaria with IgG3 antibodies in combination with the H/H131 genotype was observed. Furthermore, low levels of IgG2 antibodies reactive with the Pf332-C231 antigen were also associated with lower risk of severe malaria in individuals carrying the H131 allele. The levels of IgG1 and IgG3 antibodies were statistically significantly higher in the mild malaria patients when compared with the severe malaria patients. Taken together, our study revealed that the FcgammaRIIa-R/R131 genotype is associated with the development of severe malaria, while the H/H131 genotype is more likely to be associated with mild malaria. Our results also revealed that the natural acquisition of immunity against clinical malaria appeared to be more associated with IgG1 and IgG3 antibodies, signifying their roles in parasite-neutralizing immune mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587350     DOI: 10.1111/j.1365-3083.2007.01947.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  32 in total

1.  Genetic differentiation of populations residing in areas of high malaria endemicity in India.

Authors:  Swapnil Sinha; Vandana Arya; Sarita Agarwal; Saman Habib
Journal:  J Genet       Date:  2009-04       Impact factor: 1.166

2.  A malaria serological map indicating the intersection between parasite antigenic diversity and host antibody repertoires.

Authors:  H A Giha; A A Nasr; N C Iriemenam; K Berzins; M Troye-Blomberg; D E Arnot; G Elghazali
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-29       Impact factor: 3.267

3.  Functional haplotypes of Fc gamma (Fcγ) receptor (FcγRIIA and FcγRIIIB) predict risk to repeated episodes of severe malarial anemia and mortality in Kenyan children.

Authors:  Collins Ouma; Gregory C Davenport; Steven Garcia; Prakasha Kempaiah; Ateefa Chaudhary; Tom Were; Samuel B Anyona; Evans Raballah; Stephen N Konah; James B Hittner; John M Vulule; John M Ong'echa; Douglas J Perkins
Journal:  Hum Genet       Date:  2011-08-05       Impact factor: 4.132

4.  Assessment of the neutrophilic antibody-dependent respiratory burst (ADRB) response to Plasmodium falciparum.

Authors:  Stephanie Kapelski; Torsten Klockenbring; Rainer Fischer; Stefan Barth; Rolf Fendel
Journal:  J Leukoc Biol       Date:  2014-08-12       Impact factor: 4.962

5.  The levels of CD16/Fc gamma receptor IIIA on CD14+ CD16+ monocytes are higher in children with severe Plasmodium falciparum anemia than in children with cerebral or uncomplicated malaria.

Authors:  Lilian A Ogonda; Alloys S S Orago; Michael F Otieno; Christine Adhiambo; Walter Otieno; José A Stoute
Journal:  Infect Immun       Date:  2010-03-15       Impact factor: 3.441

6.  Antigen-specific influence of GM/KM allotypes on IgG isotypes and association of GM allotypes with susceptibility to Plasmodium falciparum malaria.

Authors:  Hayder A Giha; Amre Nasr; Nnaemeka C Iriemenam; David Arnot; Marita Troye-Blomberg; Thor G Theander; Klavs Berzins; Gehad ElGhazali; Janardan P Pandey
Journal:  Malar J       Date:  2009-12-22       Impact factor: 2.979

7.  Distinct patterns of blood-stage parasite antigens detected by plasma IgG subclasses from individuals with different level of exposure to Plasmodium falciparum infections.

Authors:  Cathrine Holm Olesen; Karima Brahimi; Brian Vandahl; Susana Lousada-Dietrich; Prajakta S Jogdand; Lasse S Vestergaard; Daniel Dodoo; Peter Højrup; Michael Christiansen; Severin Olesen Larsen; Subhash Singh; Michael Theisen
Journal:  Malar J       Date:  2010-10-26       Impact factor: 2.979

8.  FcgammaRIIa (CD32) polymorphism and anti-malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern Sudan.

Authors:  Amre Nasr; Nnaemeka C Iriemenam; Hayder A Giha; Halima A Balogun; Robin F Anders; Marita Troye-Blomberg; Gehad ElGhazali; Klavs Berzins
Journal:  Malar J       Date:  2009-03-13       Impact factor: 2.979

9.  High throughput functional assays of the variant antigen PfEMP1 reveal a single domain in the 3D7 Plasmodium falciparum genome that binds ICAM1 with high affinity and is targeted by naturally acquired neutralizing antibodies.

Authors:  Andrew V Oleinikov; Emily Amos; Isaac Tyler Frye; Eddie Rossnagle; Theonest K Mutabingwa; Michal Fried; Patrick E Duffy
Journal:  PLoS Pathog       Date:  2009-04-17       Impact factor: 6.823

10.  Marked differences in CRP genotype frequencies between the Fulani and sympatric ethnic groups in Africa.

Authors:  Elisabeth Israelsson; Mattias Ekström; Amre Nasr; Amagana Dolo; Susannah Kearsley; Gishanthi Arambepola; Manijeh Vafa Homann; Bakary Maiga; Ogobara K Doumbo; Gehad Elghazali; Hayder A Giha; Marita Troye-Blomberg; Klavs Berzins; Per Tornvall
Journal:  Malar J       Date:  2009-06-22       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.